Clinical trials: Resolution
Cataracts
Comparison of Centurion® Vision System With Balanced Tip and the Infiniti® Vision System With the Mini Flared Kelman (MFK) Tip During Cataract Extraction Surgery of Hard Lenses
The purpose of this study is to demonstrate that the Centurion® Vision System (CVS) used with the 45° Balanced Tip will result in less Cumulative Dissipated Energy (CDE) than the lnfiniti® Vision System (IVS) used with the 45°…
- Trial name
- NCT02502526
- Testing
- Centurion® Vision System, 45° Balanced Tip, Centurion® Vision System, 45° MFK Tip, lnfiniti® Vision System, 45° MFK Tip
- Volunteers
- 231 people
- Sponsor
- Alcon Research
Steroid Refractory Acute Graft Versus Host Disease
Methoxsalen and Extracorporeal Photopheresis (ECP) for the Treatment of Pediatric Participants With Steroid Refractory Acute Graft Versus Host Disease
This is a single-arm, open-label, multicenter study of the efficacy of UVADEX® (methoxsalen) Sterile Solution in conjunction with THERAKOS® CELLEX® Photopheresis Systems (ECP) in pediatric participants with steroid-refractory…
- Trial name
- NCT02524847
- Testing
- Methoxsalen, Extracorporeal Photopheresis (ECP)
- Where
- 32 sites in United States, Austria and 6 more
- Volunteers
- 29 people
- Sponsor
- Therakos, Inc., a Mallinckrodt Company
End-Stage Renal Disease
L-Carnitine as an Osmo-metabolic Agent for Peritoneal Dialysis
A major challenge of peritoneal dialysis (PD) therapy is the development of glucose-sparing strategies able to provide an efficacious ultrafiltration (UF) profile.
- Trial name
- NCT00851838
- Testing
- L-Carnitine
- Where
- Italy
- Volunteers
- 5 people
- Sponsor
- Iperboreal Pharma Srl
Healhty
Pharmacokinetics of Huperzine A Oral Solution in Healthy Participants
In this study, 4 dose groups are planned: Group 1 (0.22 mg, QD), Group 2 (0.22 mg, BID), Group 3 (0.44 mg, QD), and Group 4 (0.44 mg, BID).
- Trial name
- NCT07784335
- Testing
- Huperzine A Oral Solution
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Wanbangde Pharmaceutical Group Co., LTD
Gastroparesis, Diabetic Gastroparesis
Efficacy and Safety of Metoclopramide Nasal Spray Solution in Diabetic Patients With Gastroparesis
To evaluate the safety and the effectiveness of two doses of metoclopramide nasal spray solution, 10 mg and 14 mg, compared to placebo in reducing the symptoms of diabetic gastroparesis.
- Conditions
- Gastroparesis, Diabetic Gastroparesis, Diabetes, Diabetes Mellitus
- Trial name
- NCT00845858
- Testing
- metoclopramide
- Where
- 65 sites in United States
- Volunteers
- 287 people
- Sponsor
- Evoke Pharma
Alopecia, Androgenetic, Baldness
A Safety and Efficacy Study of PDFE-2304 Topical Solution for the Treatment of Androgenic Alopecia.
This study will evaluate the safety and efficacy of PDFE-2304 compared with Minoxidil 5% in men with androgenic alopecia (AGA).
- Conditions
- Alopecia, Androgenetic, Baldness, Androgenetic Alopecia (AGA)
- Trial name
- NEOPILI-2A (NCT07011485)
- Testing
- Minoxidil 5% Topical Solution, PDFE-2304 Topical Solution
- Where
- India
- Volunteers
- 15 people
- Sponsor
- PDFE Pharma Innovations FZCO
Knee Osteoarthritis
Evaluating the Efficacy and Safety of Intra-articular Injection of HS-20116 in Patients With Knee Osteoarthritis
The purpose of this trial is to evaluate the efficacy and safety of HS-20116 for intra-articular use in patients with symptomatic knee osteoarthritis.
- Trial name
- NCT07047196
- Testing
- HS-20116, Medical Chitosan (for intra-articular injection)
- Where
- China
- Volunteers
- 192 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Dry Eye Disease
Study of ST-100 as Treatment for Dry Eye Disease
The objective of this study is to compare the safety and efficacy of two different concentrations of ST-100 Ophthalmic Solution to placebo (vehicle) for the treatment of the signs and symptoms of dry eye.
- Trial name
- NCT05241470
- Testing
- ST-100 Ophthalmic Solution
- Where
- 3 sites in United States
- Volunteers
- 160 people
- Sponsor
- Stuart Therapeutics, Inc.
Mydriasis
Safety and Efficacy of Fixed Combination Phenylephrine-Tropicamide for Pupil Dilation
Subjects will receive ½ of the approved dose of MydCombi to determine the dilation curve with the reduced dose.
- Trial name
- NCT06217796
- Testing
- MydCombi
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Eyenovia Inc.
COVID-19
JINZHEN for Treatment of Mild to Moderate COVID-19
JINZHEN is a botanical drug that contains eight chemical constituents extracted from plant, mineral and animal origin raw materials.
- Trial name
- NCT05092503
- Testing
- JINZHEN Granules for Oral Solution
- Where
- 10 sites in United States
- Volunteers
- 60 people
- Sponsor
- Lianyungang Kanion Group, Ltd.
Healthy
A Study Comparing PF-06273340 Immediate Release Tablet, PF-06273340 Modified Release Tablets To PF-06273340 Oral Solution In The Fasted State. This Study Will Also Compare PF-06273340 Modified Release Tablets In Fasted And Fed State
The primary purpose of this study is to estimate the relative bioavailability and food effect of PF-06273340 tablets.
- Trial name
- NCT01706796
- Testing
- PF-06273340
- Where
- Singapore
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
Chemotherapy-induced Neutropenia
Plinabulin iv Solution in Prevention of TAC Induced Neutropenia
The primary purpose of this study is to compare the duration of severe neutropenia (DSN) in patients treated with: Docetaxel, doxorubicin, and cyclophosphamide (TAC) + pegfilgrastim versus Docetaxel, doxorubicin, and…
- Trial name
- NCT04227990
- Testing
- Plinabulin, Pegfilgrastim, Docetaxel, doxorubicin, and cyclophosphamide (TAC)
- Where
- 11 sites in China, Ukraine
- Volunteers
- 115 people
- Sponsor
- BeyondSpring Pharmaceuticals Inc.
Common Warts
A Study of A-101 Solution in Subjects With Common Warts.
This is a randomized, double-blind, vehicle-controlled, parallel-group study with 3 treatment groups.
- Trial name
- NCT02669862
- Testing
- A-101 Solution 40, A-101 Solution 45, Vehicle Solution
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- Aclaris Therapeutics, Inc.
Acne, Alopecia
To Evaluate the Safety, Tolerability and PK of GT20029 Gel and Solution in Healthy Subjects
The study is a randomized, double-blind, vehicle-controlled, parallel group, phase 1 study to evaluate the Safety, Tolerability and PK of GT20029 in healthy subjects
- Trial name
- NCT06468579
- Testing
- GT20029
- Where
- China
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Suzhou Kintor Pharmaceutical Inc,
Healthy Subjects
Measurement of HTL0016878 in Cerebrospinal Fluid
A Phase 1, open-label, randomised, single oral dose study to determine the concentration of HTL0016878 in CSF and plasma in healthy male subjects following dosing with HTL0016878 10 mg or 20 mg oral solution
- Trial name
- NCT04849286
- Testing
- HTL0016878
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Nxera Pharma UK Limited
Bacterial Conjunctivitis
Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Tobramycin for Bacterial Conjunctivitis (C-01-401-004)
The purpose of this study is to evaluate the clinical and microbial efficacy and safety of AzaSite compared to tobramycin for bacterial conjunctivitis.
- Trial name
- NCT00105469
- Testing
- AzaSite, Tobramycin
- Where
- 26 sites in United States
- Volunteers
- 743 people
- Sponsor
- Merck Sharp & Dohme LLC
Cystic Fibrosis, Lung Infection
Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis, Mild Lung Disease, and P. Aeruginosa
The purpose of this study was to evaluate the safety and efficacy of a 28-day course of aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis (CF), mild lung disease (forced expiratory volume in 1 second…
- Conditions
- Cystic Fibrosis, Lung Infection, Pseudomonas Aeruginosa
- Trial name
- AIR-CF4 (NCT00712166)
- Testing
- AZLI 75 mg three times daily (TID)
- Where
- 40 sites in United States, Australia and 1 more
- Volunteers
- 160 people
- Sponsor
- Gilead Sciences
Cervical Dystonia
Open Label Safety/Immunogenicity Study of MYOBLOC (Neurobloc; Botulinum Toxin Type B) in Patients With Cervical Dystonia
Open label study to evaluate the safety and immunogenicity of MYOBLOC (Botulinum Toxin Type B) in adult patients with a clinical diagnosis of Cervical Dystonia (CD).
- Trial name
- NCT00702754
- Testing
- Botulinum Toxin Type B
- Volunteers
- 502 people
- Sponsor
- Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLC
Primary Open Angle Glaucoma, Ocular Hypertension
Multicenter Study Assessing the Efficacy and Safety of DE-126 Ophthalmic Solution 0.002% Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
Reduction of elevated pressure in the eye (Intraocular pressure, or 'IOP') with eye drop medications has been shown to be effective in delaying or preventing the progression of glaucoma, and it is the only proven method for…
- Trial name
- ANGEL-2 (NCT04742283)
- Testing
- DE-126 Ophthalmic Solution 0.002% QD, Timolol Maleate Ophthalmic Solution 0.5% BID
- Where
- 41 sites in United States
- Volunteers
- 323 people
- Sponsor
- Santen Inc.
Dry Eye Disease
Efficacy and Safety of PL9643 Ophthalmic Solution in Subjects With Dry Eye
Evaluation of safety and efficacy of PL9643 Ophthalmic Solution compared to placebo for the treatment of the signs and symptoms of dry eye.
- Trial name
- NCT04268069
- Testing
- PL9643 Ophthalmic Solution
- Where
- 4 sites in United States
- Volunteers
- 160 people
- Sponsor
- ORA, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.